T-Cell Vaccination in Multiple Sclerosis (MS)

Phase 2UnknownNCT00220428

Sheba Medical Center20 enrolled

Overview

The purpose of this study is to evaluate the safety of T-cell vaccination in MS patients.

Immunization of MS patients with irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones. Clinical immunologic and neuroradiologic evaluation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

ECT

Masking

NONE

Enrollment

Conditions

Multiple Sclerosis

Interventions

T-Cell VaccinationBIOLOGICAL

Eligibility

Sex: ALLMin age: 16 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Definite MS (post criteria) * Relapsing remitting or primary progressive clinical course. At least one relapse in the last two years. * Disease duration \> 1 year * Expanded Disability Status Scale (EDSS) between 0-6 * Brain magnetic resonance imaging (MRI) compatible with MS * Not involved in any other clinical trials * No other systemic disease Exclusion Criteria: * Does not comply with the above

Locations (1)

Multiple Sclerosis Center

Ramat Gan, Israel

RECRUITING

Outcomes

Primary Outcomes

safety assessment of T-cell vaccination in nonresponding MS patients

Central Contacts

Anat Achiron, MD PhD

CONTACT

972-3-5303932 ACHIRON@POST.TAU.AC.IL

Matilda Mandel, MD

CONTACT

972-3-5305309

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.